INTERNATIONAL JOURNAL OF POLITICAL SCIENCES AND ECONOMICS
Impact Factor (research bib) - 9,78
https://ijmri.de/index.php/ijpse , German international journals company
ISSN 2751-9708

CHRONIC HEART FAILURE (CHF) AND NEW DRUGS: ANALYTICAL REVIEW OF EFFICACY

Sayyora Muhammadova
2nd-year student, Faculty of Medicine, Kokand University, Andijan Branch
saloxitdinoagavxaroy@gmail.com

Abstract: Chronic heart failure (CHF) is a multifactorial clinical syndrome characterized by impaired cardiac pumping function, reduced exercise tolerance, and frequent hospitalizations, posing a significant global health burden. Traditional pharmacotherapy, including ACE inhibitors, beta-blockers, and diuretics, improves symptoms and survival but often fails to fully address disease progression or quality of life. Recent advances in pharmacology have introduced novel therapeutic agents targeting key pathophysiological mechanisms in CHF, including angiotensin–neprilysin inhibitors (ARNIs), sodium–glucose cotransporter-2 (SGLT2) inhibitors, myotropic agents, and anti-inflammatory drugs. These therapies aim to enhance cardiac function, optimize neurohormonal balance, improve myocardial energetics, and reduce systemic inflammation.

Sacubitril/valsartan, an ARNI, combines angiotensin receptor blockade with neprilysin inhibition, enhancing natriuretic peptide activity and promoting vasodilation. Clinical trials demonstrate reduced mortality and hospitalization rates, improved symptom management, and long-term survival benefits in patients with reduced ejection fraction. SGLT2 inhibitors, originally developed for diabetes management, including empagliflozin, have shown cardioprotective effects by reducing renal sodium and glucose reabsorption, promoting diuresis, and enhancing ventricular performance, independent of glycemic control. Omecamtiv mecarbil, a myotropic agent, improves myocardial contractility by stimulating cardiac myosin, demonstrating increased cardiac output in early studies. Anti-inflammatory therapies, such as ziltivekimab, are under investigation for modulating interleukin-6–mediated chronic inflammation that contributes to cardiac and vascular dysfunction.

Evidence from major international guidelines, including ACCF/AHA 2022 and ESC 2023, emphasizes the integration of these novel therapies with standard care to optimize neurohormonal regulation, mitigate disease progression, and address comorbidities such as iron deficiency. Comparative analyses highlight that ARNIs and SGLT2 inhibitors consistently produce favorable outcomes in mortality reduction, hospitalizations, and functional capacity, whereas myotropic and anti-inflammatory agents are emerging as promising adjuncts in selected patient populations. Safety profiles are generally acceptable, but long-term data and individualized therapy considerations remain critical for optimal clinical application.

Keywords: Chronic heart failure, novel drugs, angiotensin–neprilysin inhibitors, SGLT2 inhibitors, pharmacotherapy, clinical trials, sacubitril/valsartan, empagliflozin, omecamtiv mecarbil, interleukin-6 inhibitors

Introduction

Chronic heart failure (CHF) is characterized by the heart's reduced ability to pump blood, due to systolic or diastolic dysfunction, which results in insufficient oxygen delivery to peripheral tissues. Leading causes include ischemic heart disease, hypertension, previous

myocardial infarction, and cardiomyopathies. Clinically, CHF manifests with fatigue, dyspnea, peripheral edema, and exercise intolerance.

CHF is prevalent worldwide, especially among the elderly, and is associated with high rates of hospitalization and mortality. Modern guidelines recommend early pharmacotherapy to slow disease progression, improve symptoms, and prolong survival. Traditional treatments include diuretics, ACE inhibitors, and beta-blockers. However, many patients continue to experience persistent symptoms and progressive cardiac dysfunction.

Consequently, clinical researchers have focused on developing novel therapies targeting broader pathophysiological mechanisms. These include drugs that improve cardiac energetics, suppress neurohormonal overactivation, and exert anti-inflammatory effects. Such approaches aim to provide additional clinical benefits beyond conventional therapy.

Main Body

Overview of Chronic Heart Failure and Pathophysiology

Chronic heart failure (CHF) is a complex clinical syndrome defined by the heart's inability to pump sufficient blood to meet the body's metabolic demands. It may result from systolic dysfunction, characterized by reduced ejection fraction, or diastolic dysfunction, marked by impaired ventricular relaxation. Leading causes include ischemic heart disease, hypertension, prior myocardial infarction, and cardiomyopathies. The syndrome manifests clinically with fatigue, dyspnea, peripheral edema, reduced exercise tolerance, and frequent hospitalizations. CHF prevalence increases with age, and it poses a significant public health burden worldwide due to high morbidity, mortality, and healthcare costs.

The pathophysiology of CHF is multifactorial, involving neurohormonal activation, myocardial remodeling, endothelial dysfunction, and systemic inflammation. Overactivation of the renin-angiotensin-aldosterone system (RAAS) and sympathetic nervous system contributes to progressive ventricular dysfunction. Chronic inflammation and oxidative stress further exacerbate myocardial injury, promoting fibrosis and maladaptive remodeling. These mechanisms underscore the need for targeted pharmacological interventions that not only alleviate symptoms but also modify disease progression and improve long-term outcomes.

Angiotensin–Neprilysin Inhibitors

Sacubitril/valsartan, an angiotensin receptor–neprilysin inhibitor (ARNI), represents a major advance in CHF management. Sacubitril inhibits neprilysin, an enzyme responsible for degrading natriuretic peptides, bradykinin, and other vasoactive peptides. This inhibition enhances natriuretic peptide activity, promoting vasodilation, natriuresis, and diuresis while reducing cardiac stress. Valsartan, an angiotensin receptor blocker, mitigates RAAS-mediated vasoconstriction and sodium retention.

Clinical trials, including the pivotal PARADIGM-HF study, demonstrate that sacubitril/valsartan significantly reduces cardiovascular mortality and heart failure hospitalization compared to enalapril, a standard ACE inhibitor. Symptom improvement, functional status enhancement, and long-term survival benefits are consistently observed. Adverse events are generally manageable, with hypotension and mild hyperkalemia being the

most common. ARNIs are now recommended as a first-line therapy in patients with heart failure with reduced ejection fraction (HFrEF), emphasizing early initiation for optimal benefit.

SGLT2 Inhibitors

Sodium–glucose cotransporter-2 (SGLT2) inhibitors, such as empagliflozin, were initially developed for type 2 diabetes management. These agents reduce renal glucose and sodium reabsorption, leading to osmotic diuresis, mild natriuresis, and blood pressure reduction. Surprisingly, large clinical trials, including DAPA-HF and EMPEROR-Reduced, have demonstrated that SGLT2 inhibitors significantly improve cardiovascular outcomes in CHF patients, irrespective of diabetes status.

Empagliflozin improves ventricular loading conditions, reduces interstitial fluid accumulation, and promotes favorable myocardial energetics. Patients experience decreased hospitalizations, improved exercise tolerance, and enhanced quality of life. Additionally, SGLT2 inhibitors appear to reduce systemic inflammation and oxidative stress, contributing to their cardioprotective effects. Safety profiles are favorable, with low risk of hypotension and minimal electrolyte disturbances, making them suitable for broad CHF populations.

Myotropic Agents

Omecamtiv mecarbil is a novel myotropic agent that directly enhances myocardial contractility by activating cardiac myosin. Unlike traditional inotropes, omecamtiv mecarbil does not increase intracellular calcium levels, thereby reducing the risk of arrhythmias and myocardial oxygen consumption. Early-phase clinical trials demonstrate that it increases systolic ejection time and stroke volume, improving cardiac output in patients with HFrEF.

Omecamtiv mecarbil is particularly promising for patients with persistent low cardiac output despite standard therapy. While long-term efficacy and safety data are still under investigation, preliminary results suggest potential benefits in reducing heart failure hospitalization and improving exercise capacity. This mechanism of action complements existing therapies, targeting contractile dysfunction directly rather than neurohormonal modulation.

Anti-Inflammatory Agents

Chronic inflammation contributes significantly to CHF progression. Ziltivekimab, a monoclonal antibody targeting interleukin-6 (IL-6), is under investigation for its potential to reduce systemic inflammation affecting cardiac, renal, and vascular systems. By modulating inflammatory signaling pathways, ziltivekimab may prevent adverse cardiac remodeling and improve functional outcomes. Although clinical efficacy in CHF is still being evaluated, early-phase studies indicate reductions in inflammatory biomarkers and potential cardioprotective effects. Anti-inflammatory therapy represents an emerging adjunctive approach, particularly in patients with inflammatory-driven heart failure phenotypes.

Integration with Standard Therapy

Current guidelines, including ACCF/AHA 2022 and ESC 2023, emphasize a multi-agent approach combining ARNIs, SGLT2 inhibitors, beta-blockers, and mineralocorticoid receptor antagonists. Such combinations optimize neurohormonal modulation, improve hemodynamics,

and mitigate disease progression. Addressing comorbidities, such as iron deficiency, anemia, and renal impairment, further enhances functional capacity and quality of life. The integration of novel agents allows for personalized therapy based on patient-specific characteristics, risk profiles, and treatment tolerance.

Clinical Outcomes and Limitations

Novel pharmacological agents demonstrate consistent improvements in survival, reduction in hospitalization rates, and enhanced symptom management. ARNIs and SGLT2 inhibitors have the strongest evidence base, while myotropic and anti-inflammatory agents are emerging options with promising preliminary results. However, efficacy depends on patient adherence, baseline comorbidities, and concomitant therapies. Long-term safety data for newer agents, particularly myotropic and anti-inflammatory drugs, remain limited. Additionally, cost considerations and accessibility may affect real-world implementation.

Results and Analysis

Novel drugs, particularly ARNIs and SGLT2 inhibitors, show significant clinical improvements in CHF patients. Key outcomes include reduced mortality, decreased hospitalizations, and improved cardiac function. Additional benefits arise from improved cardiac energetics and reduced systemic inflammation.

However, efficacy depends on patient status, comorbidities, and concomitant therapies. Long-term safety data are still being collected.

Conclusion

Chronic heart failure (CHF) remains one of the most prevalent and challenging cardiovascular syndromes worldwide, characterized by impaired cardiac pumping function, progressive ventricular remodeling, and significant morbidity and mortality. Despite decades of therapeutic advancements with conventional pharmacotherapy, including ACE inhibitors, beta-blockers, and diuretics, many patients continue to experience persistent symptoms, recurrent hospitalizations, and reduced quality of life. The limitations of traditional treatments have driven extensive research into novel pharmacological agents targeting key pathophysiological pathways in CHF.

Recent innovations, particularly angiotensin–neprilysin inhibitors (ARNIs) and sodium–glucose cotransporter-2 (SGLT2) inhibitors, have demonstrated robust clinical efficacy in multiple large-scale trials. Sacubitril/valsartan, an ARNI, provides dual benefits by enhancing natriuretic peptide activity while blocking detrimental RAAS signaling, resulting in reduced cardiovascular mortality, fewer hospitalizations, and improved functional status in patients with heart failure with reduced ejection fraction. SGLT2 inhibitors, including empagliflozin, have shown significant cardioprotective effects independent of glycemic control, improving cardiac energetics, reducing interstitial fluid overload, and enhancing exercise tolerance. These agents represent a paradigm shift in CHF management, emphasizing the integration of novel mechanisms beyond conventional neurohormonal blockade.

Emerging therapies, such as myotropic agents like omecamtiv mecarbil, offer a promising approach to directly augment myocardial contractility without increasing intracellular calcium

levels, potentially reducing arrhythmic risk and oxygen consumption. Anti-inflammatory drugs, including IL-6 inhibitors such as ziltivekimab, aim to mitigate systemic inflammation, a recognized contributor to adverse cardiac remodeling and functional decline. Although these therapies are still under investigation, preliminary evidence suggests potential benefits in selected patient populations, particularly those with persistent low-output states or inflammatory-driven disease phenotypes.

Integration of novel agents with standard therapy, as emphasized by current ACCF/AHA 2022 and ESC 2023 guidelines, enables a comprehensive, individualized treatment approach. Combining ARNIs, SGLT2 inhibitors, beta-blockers, and mineralocorticoid receptor antagonists addresses multiple pathophysiological mechanisms simultaneously, optimizing hemodynamics, mitigating disease progression, and improving quality of life. Management of comorbidities, including iron deficiency, renal impairment, and anemia, further enhances patient outcomes and functional capacity.

While the clinical benefits of these new therapies are evident, long-term safety data, patient adherence, cost considerations, and accessibility remain critical factors influencing real-world implementation. Individualized therapy selection based on patient characteristics, disease severity, and tolerance is essential to maximize therapeutic efficacy and minimize adverse effects.

In conclusion, the evolution of CHF pharmacotherapy highlights the transformative impact of novel agents in improving survival, reducing hospitalization, and enhancing functional outcomes. ARNIs and SGLT2 inhibitors currently represent the most evidence-based innovations, whereas myotropic and anti-inflammatory therapies offer emerging adjunctive options. Continued research and clinical trials will expand the therapeutic arsenal, enabling clinicians to provide tailored, effective, and comprehensive care. Early implementation of these therapies, alongside standard management and multidisciplinary support, holds the potential to significantly improve long-term prognosis, patient well-being, and overall quality of life for individuals living with CHF.

References

1. Heidenreich, P., & Sandhu, A. (2024). Advances in management of heart failure. BMJ. https://www.bmj.com/content/385/bmj-2023-077025
2. PubMed. (2025). New drugs for the treatment of chronic heart failure with a reduced ejection fraction. https://pubmed.ncbi.nlm.nih.gov/31397687
3. Xaydarov, A. X., Mamatkulova, F., & Uzoqova, O. N. (2025). Modern approaches to iron deficiency treatment in chronic heart failure patients. Science and Education. https://openscience.uz/index.php/sciedu/article/view/7446
4. Ubaydullayeva, S. R. (2023). Chronic heart failure: pathology and treatment. BestPublication.org. https://bestpublication.org/index.php/pedg/article/view/3670
5. Ozodlik.uz. (n.d.). Heart failure statistics and treatment approaches.
6. Wikipedia contributors. (2025). Ziltivekimab. https://en.wikipedia.org/wiki/Ziltivekimab
7. The Sun. (2026). New Ozempic pill slashes risk of deadly heart issues. https://www.thesun.co.uk/health/38096426/ozempic-pill-slashes-heart-failure-risk